ESR1 and breast cancer: Previous work has indicated that miR-22 directly targets ERα, it is downregulated in ERα + breast cancer cell lines and clinical samples54, and it can sensitize bladder carcinoma55 and resensitize paclitaxel-resistant colon cancer cells23 to paclitaxel.